Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that a lack of interest in the niche bladder cancer market is resulting in a shortage of available candidate drugs. The lack of clinical trials with biological, targeted agents is slowing progress in this disease, resulting in a constrained market.

"Thought leaders attribute the lack of clinical trials to both a lack of available candidate drugs and a lack of interest in the niche market," said Clair Gricks, Ph.D., analyst at Decision Resources. "However, a large commercial opportunity in bladder cancer lies in the development of a biological targeted agent. The first such therapy to reach the market will likely enjoy great success."

The new Pharmacor study entitled Bladder Cancer also finds that Eli Lilly's Gemzar is being investigated as an intravesical therapy for recurrent superficial bladder cancer. Phase II studies showed a complete response in 56% of patients with recurring intermediate-risk superficial bladder cancer. Physicians report the need for alternative therapies in this group of patients due to the high rate of recurrence.

Current Treatment for Bladder Cancer

Bacillus Calmette-Guerin (BCG) is the current standard of care for high- risk superficial bladder cancer and patients with recurring intermediate/high- risk superficial bladder cancer. However, approximately 50% of high-risk patients will recur or progress after BCG treatment. Also, BCG is associated with significant morbidity and infection.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Sales of Oral Topotecan for the Treatment of Small-Cell Lung Cancer will Reach $103 Million in 2013

View Now